NASDAQ:STAA - STAAR Surgical Stock Price, Forecast & News

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

STAAR Surgical (NASDAQ:STAA) issued its earnings results on Wednesday, October, 30th. The medical instruments supplier reported $0.05 earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of $0.05. The medical instruments supplier earned $39.06 million during the quarter, compared to the consensus estimate of $37.50 million. STAAR Surgical had a return on equity of 13.84% and a net margin of 6.15%. View STAAR Surgical's Earnings History.

STAAR Surgical is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for STAAR Surgical.

STAAR Surgical issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $150.2-150.2 million, compared to the consensus revenue estimate of $149.45 million.

3 Wall Street analysts have issued 12-month target prices for STAAR Surgical's shares. Their forecasts range from $45.00 to $56.00. On average, they anticipate STAAR Surgical's share price to reach $49.00 in the next twelve months. This suggests a possible upside of 65.1% from the stock's current price. View Analyst Price Targets for STAAR Surgical.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STAAR Surgical.

Press coverage about STAA stock has been trending somewhat negative on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. STAAR Surgical earned a news impact score of -1.5 on InfoTrie's scale. They also assigned media stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for STAAR Surgical.

STAAR Surgical saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 4,250,000 shares, an increase of 7.6% from the January 15th total of 3,950,000 shares. Based on an average daily volume of 393,400 shares, the days-to-cover ratio is presently 10.8 days. Approximately 9.7% of the shares of the stock are sold short. View STAAR Surgical's Current Options Chain.

Some companies that are related to STAAR Surgical include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), DENTSPLY SIRONA (XRAY), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), Atrion (ATRI), Cerus (CERS), Anika Therapeutics (ANIK), Antares Pharma (ATRS), OraSure Technologies (OSUR) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include NVIDIA (NVDA), Rockwell Medical (RMTI), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Vanda Pharmaceuticals (VNDA), Agile Therapeutics (AGRX), Amarin (AMRN), Immunomedics (IMMU), Karyopharm Therapeutics (KPTI) and TG Therapeutics (TGTX).

STAAR Surgical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Palo Alto Investors LP (8.48%), Baillie Gifford & Co. (4.36%), Capital International Investors (4.12%), State Street Corp (2.56%), Janus Henderson Group PLC (1.98%) and Defender Capital LLC. (1.35%). Company insiders that own STAAR Surgical stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Graydon C Hansen, Jon K Hayashida, Keith Holliday, Samuel J Gesten, Scott D Barnes and William P Wall. View Institutional Ownership Trends for STAAR Surgical.

STAA stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Barclays PLC, Palo Alto Investors LP, State Street Corp, BosValen Asset Management Ltd, Principal Financial Group Inc., King Luther Capital Management Corp and Chicago Equity Partners LLC. Company insiders that have sold STAAR Surgical company stock in the last year include Caren L Mason, Deborah J Andrews, Graydon C Hansen, Jon K Hayashida, Keith Holliday, Samuel J Gesten and Scott D Barnes. View Insider Buying and Selling for STAAR Surgical.

STAA stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Broadfin Capital LLC, Loomis Sayles & Co. L P, UBS Asset Management Americas Inc., Janus Henderson Group PLC, Royce & Associates LP, Bank of America Corp DE and Driehaus Capital Management LLC. View Insider Buying and Selling for STAAR Surgical.

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of STAA stock can currently be purchased for approximately $29.67.

STAAR Surgical has a market capitalization of $1.32 billion and generates $123.95 million in revenue each year. The medical instruments supplier earns $4.97 million in net income (profit) each year or $0.28 on an earnings per share basis. STAAR Surgical employs 475 workers across the globe.View Additional Information About STAAR Surgical.

The official website for STAAR Surgical is http://www.staar.com/.

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]